228 related articles for article (PubMed ID: 28027591)
1. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
[TBL] [Abstract][Full Text] [Related]
2. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.
Musso G; Cipolla U; Cassader M; Pinach S; Saba F; De Michieli F; Paschetta E; Bongiovanni D; Framarin L; Leone N; Berrutti M; Rosina F; Corvisieri S; Molinaro F; Sircana A; Gambino R
J Lipid Res; 2017 Jun; 58(6):1221-1229. PubMed ID: 28242789
[TBL] [Abstract][Full Text] [Related]
3. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
4. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
7. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.
Mahdessian H; Taxiarchis A; Popov S; Silveira A; Franco-Cereceda A; Hamsten A; Eriksson P; van't Hooft F
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8913-8. PubMed ID: 24927523
[TBL] [Abstract][Full Text] [Related]
8. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.
Goffredo M; Caprio S; Feldstein AE; D'Adamo E; Shaw MM; Pierpont B; Savoye M; Zhao H; Bale AE; Santoro N
Hepatology; 2016 Jan; 63(1):117-25. PubMed ID: 26457389
[TBL] [Abstract][Full Text] [Related]
9. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
[TBL] [Abstract][Full Text] [Related]
10. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
11. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
[TBL] [Abstract][Full Text] [Related]
12. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Kozlitina J; Smagris E; Stender S; Nordestgaard BG; Zhou HH; Tybjærg-Hansen A; Vogt TF; Hobbs HH; Cohen JC
Nat Genet; 2014 Apr; 46(4):352-6. PubMed ID: 24531328
[TBL] [Abstract][Full Text] [Related]
13. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
Bódis K; Bombrich M; Schön M; Knebel B; Zaharia OP; Bönhof G; Karusheva Y; Strassburger K; Kupriyanova Y; Kotzka J; Guthoff R; Schrauwen-Hinderling V; Al-Hasani H; Burkart V; Szendroedi J; Wagner R; Markgraf DF; Roden M;
Nutr Metab Cardiovasc Dis; 2023 Sep; 33(9):1785-1796. PubMed ID: 37495452
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice.
Fan Y; Lu H; Guo Y; Zhu T; Garcia-Barrio MT; Jiang Z; Willer CJ; Zhang J; Chen YE
Gastroenterology; 2016 May; 150(5):1208-1218. PubMed ID: 26774178
[TBL] [Abstract][Full Text] [Related]
15. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
16. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
Luo F; Oldoni F; Das A
Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
18. Perturbation of
Pant A; Chen Y; Kuppa A; Du X; Halligan BD; Speliotes EK
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575933
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
20. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
